Currently, multiple phase I/II clinical trials in patients with solid tumors or hematologic malignancies are ongoing for these checkpoint inhibitors, including anti-TIM3 (e.g., NCT03489343), anti-LAG3 (e.g., NCT03005782), and anti-TIGIT (e.g., NCT04354246), as well as combination therapies, such as the combination of anti-TIM3, anti-PD-1, and anti-LAG3 (NCT04370704) and the combination of anti-LAG3 with anti-TIGIT (NCT04150965). The gene discussed is TIGIT; the disease is hematologic disorder.